Drug Search Results
More Filters [+]

Prasugrel

Alternative Names: prasugrel, cs-747, effient
Latest Update: 2024-09-25
Latest Update Note: Clinical Trial Update

Product Description

Prasugrel, trade name Effient, is an investigational new antiplatelet drug currently under review for clinical use by the Food and Drug Administration. It is a thienopyridine analog with a structure similar to that of clopidogrel and ticlopidine. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/18923235/)

Mechanisms of Action: P2Y12 Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lithuania | Luxembourg | Malta | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: Acute Coronary Syndrome | Coronary Thrombosis | Myocardial Infarction | Thrombosis | Angina, Stable | Angina, Unstable

Known Adverse Events: Injuries/wounds Unspecified

Company: Cosette Pharmaceuticals
Company Location:
Company CEO:
Additonal Commercial Interests: Daiichi Sankyo

Clinical Description

Map of Global Clinical Trials for Prasugrel

Countries in Clinic: Australia, Belgium, Canada, Colombia, Croatia, Germany, Hungary, India, Ireland, Japan, Nepal, Netherlands, New Zealand, Pakistan, Portugal, Romania, Saudi Arabia, Spain, United Kingdom, United States

Active Clinical Trial Count: 5

Highest Development Phases

Phase 3: COVID-19|Coronary Artery Disease|Influenza, Human|Pneumonia

Phase 2: Atherosclerosis

Phase 1: Healthy Volunteers|Oncology Solid Tumor Unspecified

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2023-507015-35-00

P3

Not yet recruiting

Coronary Artery Disease

2029-07-30

ANGIODAPT

P3

Active, not recruiting

Coronary Artery Disease

2029-07-21

REMAP-CAP

P3

Recruiting

Pneumonia|Influenza, Human|COVID-19

2026-02-01

SYNIVUS-DAPT

P2

Active, not recruiting

Coronary Artery Disease|Atherosclerosis

2021-12-31

Recent News Events